GlassScriptPhysician profile
David H Kim
NPI 1891964441
$6,974.87
in general payments reported to CMS, 2019-2025
29 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $265 · 2021: $457 · 2022: $921 · 2023: $1,724 · 2024: $884 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Entertainment: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.24 |
| Entertainment | $197.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,578.91 | 2019-2025 | Watchman Access System, Watchman |
| Terumo Medical Corporation | $822.22 | 2020-2023 | Navicross, Azur Cx Detachable |
| Novartis Pharmaceuticals Corporation | $712.52 | 2021-2025 | |
| Abbott Laboratories | $466.41 | 2022-2024 | Cardiomems, Jot Dx |
| Depuy Synthes Sales INC. | $384.11 | 2023-2025 | Na, Lcp, Motoband |
| Abiomed | $356.88 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $353.06 | 2020-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $324.10 | 2019-2020 | |
| Opsens INC. | $287.90 | 2022-2023 | Optowire |
| Heartflow, INC. | $249.07 | 2023-2024 | Ffrct |
| Amgen INC. | $198.85 | 2021-2025 | Repatha, Repatha |
| Penumbra, INC. | $198.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $196.46 | 2022-2023 | Onpattro |
| Pfizer INC. | $156.81 | 2019-2025 | |
| Medtronic, INC. | $110.05 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $94.98 | 2021-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $86.38 | 2022-2024 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $79.51 | 2021-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.12 | 2022 | |
| Scpharmaceuticals INC. | $42.05 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.97 | 2023-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $40.76 | 2019-2024 | |
| Edwards Lifesciences Corporation | $38.90 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cvrx, INC. | $26.16 | 2025 | Barostim Neo System |
| Takeda Pharmaceuticals U.S.A., INC. | $22.22 | 2023 | Entyvio |
| Ardelyx, INC. | $20.78 | 2024 | Ibsrela |
| Biosense Webster, INC. | $16.70 | 2022 | |
| Merck Sharp & Dohme LLC | $14.04 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.